Black Diamond Therapeutics Inc
NASDAQ:BDTX

Watchlist Manager
Black Diamond Therapeutics Inc Logo
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Watchlist
Price: 4.87 USD -7.06% Market Closed
Updated: May 19, 2024

Black Diamond Therapeutics Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Black Diamond Therapeutics Inc
Interest Income Expense Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Interest Income Expense
$1.9m
CAGR 3-Years
-22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$1.8B
CAGR 3-Years
11%
CAGR 5-Years
-6%
CAGR 10-Years
-18%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$663m
CAGR 3-Years
38%
CAGR 5-Years
3%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-44%
CAGR 5-Years
-30%
CAGR 10-Years
-16%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$630.1m
CAGR 3-Years
93%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$221.8m
CAGR 3-Years
-13%
CAGR 5-Years
75%
CAGR 10-Years
N/A

See Also

What is Black Diamond Therapeutics Inc's Interest Income Expense?
Interest Income Expense
1.9m USD

Based on the financial report for Dec 31, 2023, Black Diamond Therapeutics Inc's Interest Income Expense amounts to 1.9m USD.

What is Black Diamond Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-22%

The average annual Interest Income Expense growth rates for Black Diamond Therapeutics Inc have been -22% over the past three years .